简言之：恩帕列嗪（Jardiance）治疗慢性肾脏疾病。

IF 1.4 4区医学 Q4 PHARMACOLOGY & PHARMACY

Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-13 DOI:10.58347/tml.2023.1689c

{"title":"简言之：恩帕列嗪（Jardiance）治疗慢性肾脏疾病。","authors":"","doi":"10.58347/tml.2023.1689c","DOIUrl":null,"url":null,"abstract":"The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. It is also approved to improve glycemic control in patients ≥10 years old with type 2 diabetes, to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with HF, and to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":"65 1689","pages":"183-184"},"PeriodicalIF":1.4000,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In brief: Empagliflozin (Jardiance) for chronic kidney disease.\",\"authors\":\"\",\"doi\":\"10.58347/tml.2023.1689c\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. It is also approved to improve glycemic control in patients ≥10 years old with type 2 diabetes, to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with HF, and to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.\",\"PeriodicalId\":54742,\"journal\":{\"name\":\"Medical Letter on Drugs and Therapeutics\",\"volume\":\"65 1689\",\"pages\":\"183-184\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Letter on Drugs and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.58347/tml.2023.1689c\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Letter on Drugs and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.58347/tml.2023.1689c","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

In brief: Empagliflozin (Jardiance) for chronic kidney disease.

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. It is also approved to improve glycemic control in patients ≥10 years old with type 2 diabetes, to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with HF, and to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Medical Letter on Drugs and Therapeutics 医学-药学

CiteScore

1.00

自引率

42.10%

发文量

审稿时长

6-12 weeks

期刊介绍： The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry. The Medical Letter On Drugs and Therapeutics is a biweekly publication that provides: Evidence-based, peer-reviewed evaluations of new FDA-approved drugs with conclusions reached by a consensus of experts New information on previously approved drugs including pivotal clinical trials, new indications, and safety warnings Consensus recommendations for the preferred and alternative treatments for common disorders Comparative reviews of drugs for a given indication with particular attention to clinical efficacy, adverse effects, drug interactions, and cost.